Vaderis erhält FDA Fast Track Designation für VAD044 zur Behandlung der hereditären hämorrhagischen Telangiektasie

Vaderis Therapeutics AG Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom Maryland United States of America Canada Europe

View original content:https://www.prnewswire.com/news-releases/vaderis-erhalt-fda-fast-track-designation-fur-vad044-zur-behandlung-der-hereditaren-hamorrhagischen-telangiektasie-302307636.html